<DOC>
	<DOCNO>NCT00193193</DOCNO>
	<brief_summary>In trial investigate three-drug regimen may improve , respect efficacy toxicity , make modification dose schedule treatment patient hormone refractory prostate cancer .</brief_summary>
	<brief_title>Weekly Paclitaxel , Low-Dose Estramustine , Carboplatin Treatment Hormone Refractory Prostate Carcinoma</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : Paclitaxel + Estramustine + Carboplatin Patients receive weekly paclitaxel low-dose estramustine , combination carboplatin administer either weekly r every four week .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Adenocarcinoma prostate curable local treatment Disease progression receive hormonal therapy Measurable evaluable disease Previous treatment maximum one prior chemotherapy regimen ECOG performance status 0 , 1 , 2 . Adequate bone marrow , liver kidney function Able comprehend nature study give write informed consent You participate study follow apply : Age &lt; 18 year History treatment invasive malignancy within five year Significant heart disease Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>